Sheridan Capital Partners, a Chicago-based healthcare private equity firm, has taken an ownership stake in Advi Health, a market access, commercialization and policy consulting firm.

Advi combines the advice, action and tools of traditional consulting with the vision of corporate strategy to serve its clients. The firm’s intelligence, datasets and advocacy aim to drive cell and gene, vaccine, rare and ultra-rare disease therapies as well as oncology therapies, digital therapeutics, AI advances, diagnostics and medical technology. Together, the companies look to drive, strengthen and extend Advi’s position through the expansion of its services and product offerings. Sheridan invested alongside Advi senior leaders, who retained an ownership stake in the business and will remain active in the leadership and operations of the company.

ADVI’s team represents a platform we will support and grow to help companies and organizations around the world navigate the complex policy, regulatory and reimbursement changes that are shaping our evolving healthcare landscape,” comments Nicholas Rowland, partner at Sheridan.

Clearsight Advisors Inc. served as financial advisor and Greenberg Traurig served as legal counsel to Advi in connection with this transaction. McDermott Will & Emery LLP served as legal counsel to Sheridan. Twin Brook Capital Partners provided debt financing for the transaction.